Cashu | News | HAE

HomeWatchlistNewsSignalsPicks

DJI

+0.08%

SPX

-0.22%

IXIC

-0.51%

FTSE

-0.20%

N225

-0.22%

AXJO

-0.21%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Latest Haemonetics News

U.S. Food and Drug Administration Approves CSL's ANDEMBRY (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start

Feature Image for interests on Biotechnology, Clinical Trials & Medical Discoveries, Fda Approval, Health Care & Hospitals from prnewswire.com

Haemonetics Announces Executive Leadership Updates

Feature Image for interests on Health Care & Hospitals, Healthcare, Medical Equipment, Medical Pharmaceuticals from prnewswire.com

Die Europische Arzneimittelagentur (EMA) hat eine zustzliche Option zur subkutanen Verabreichung von TAKHZYRO (Lanadelumab) fr Patienten ab 12 Jahren mit wiederkehrenden Attacken des hereditren Angiodems (HAE) genehmigt

Feature Image for interests on Clinical Trials & Medical Discoveries, Health Care & Hospitals, Healthcare, International Medical Approval from prnewswire.com

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Feature Image for interests on Clinical Trials & Medical Discoveries, Health Care & Hospitals, Healthcare, International Medical Approval from prnewswire.com

CSL Receives Approval in Japan for ANDEMBRY (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)

Feature Image for interests on Health Care & Hospitals, Healthcare, Japan, Medical Pharmaceuticals from prnewswire.com

European Commission Approves CSL's ANDEMBRY (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

Feature Image for interests on Health Care & Hospitals, Healthcare, Medical Pharmaceuticals, Otc from prnewswire.com

Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A

Feature Image for interests on Acquisitions, Health Care & Hospitals, Healthcare, Medical Equipment from prnewswire.com

businesswire.com

SpectraWAVE Appoints Brad Davis as Chief Commercial Officer and Bill Kelly as Chief Financial Officer

Feature Image for interests on Healthcare, Stock from businesswire.com

businesswire.com

SpectraWAVE Appoints Brad Davis as Chief Commercial Officer and Bill Kelly as Chief Financial Officer

Feature Image for interests on Healthcare, Stock from businesswire.com

CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

Feature Image for interests on Biotechnology, Health Care & Hospitals, Healthcare, Industrials from prnewswire.com

Stocks

Health Care

hae

Haemonetics

HAE

+1.11 (+1.58%)

71.17

USD

At close at Jun 20, 20:37 UTC

Latest Cashu News

Haemonetics Stock Impacted by CSL's FDA Approval of ANDEMBRY for Hereditary Angioedema

Haemonetics Strengthens Leadership for Innovation and Operational Excellence in Healthcare Technology

Haemonetics Appoints Leadership to Boost Innovation and Operational Excellence in Healthcare